Sectors & IndustriesHealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2025)
Top general drug manufacturer stocks in 2025 ranked by overall Due Diligence Score. See the best general drug manufacturer stocks to buy now, according to analyst forecasts for the drug manufacturers - general industry.

Industry: Drug Manufacturers - Gene...
Ticker
Company
Dividends Score
Market Cap
Dividend Yield
Payout Ratio
Last Dividend
Annual Dividend
Dividend Percentile
Dividend Dropped Count (L10Y)
Ex-dividend Date
Div. Payment Date
MRK
MERCK & CO INC
$213.55B3.70%64.30%$0.8100$3.1274%02025-03-172025-04-07
LLY
ELI LILLY & CO
$827.67B0.45%54.10%$1.3000$3.908%02025-02-142025-03-10
AZN
ASTRAZENECA PLC
$230.80B1.99%65.40%$0.5000$1.4948%102025-02-212025-03-24
BIIB
BIOGEN INC
$20.27BN/A0.00%N/AN/AN/AN/A
JNJ
JOHNSON & JOHNSON
$378.60B3.12%84.10%$1.2400$4.9167%02025-02-182025-03-04
SNY
SANOFI
$136.39B3.77%88.10%$2.0374$2.0475%1
PFE
PFIZER INC
$145.30B4.91%219.70%$0.4200$1.2684%02025-03-07
NVS
NOVARTIS AG
$212.74B3.51%63.80%$3.7772$3.7872%2
ABBV
ABBVIE INC
$341.85B2.40%215.30%$1.5500$4.6556%02025-02-14
GSK
GSK PLC
$74.58B4.26%98.50%$0.3891$1.5679%10
AMGN
AMGEN INC
$159.63B3.03%112.50%$2.2500$9.0066%02025-02-142025-03-07
GILD
GILEAD SCIENCES INC
$132.05B2.91%3,060.00%$0.7700$3.0863%0
GRFS
GRIFOLS SA
$5.14BN/A0.00%$0.4562N/AN/A3
OGN
ORGANON & CO
$4.20B1.72%22.10%$0.2800$0.2841%0
BMY
BRISTOL MYERS SQUIBB CO
$113.58B3.22%-40.80%$0.6000$1.8068%0
SCLX
SCILEX HOLDING CO
$84.92MN/A0.00%N/AN/AN/AN/A
AMRN
AMARIN CORP PLC
$248.86MN/A0.00%N/AN/AN/AN/A
MIRA
MIRA PHARMACEUTICALS INC
$19.71MN/A0.00%N/AN/AN/AN/A

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Feb 2025?

According to Due Diligence Score, the 3 best general drug manufacturer stocks to buy right now are:

1. Merck & Co (NYSE:MRK)


Merck & Co (NYSE:MRK) is the top general drug manufacturer stock with a Due Diligence Score of 63, which is 23 points higher than the general drug manufacturer industry average of 40. It passed 23 out of 38 due diligence checks and has strong fundamentals. Merck & Co has seen its stock lose -32.7% over the past year, underperforming other general drug manufacturer stocks by -37 percentage points.

Merck & Co has an average 1 year price target of $119.00, an upside of 40.96% from Merck & Co's current stock price of $84.42.

Merck & Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Merck & Co, 58.33% have issued a Strong Buy rating, 8.33% have issued a Buy, 33.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Eli Lilly & Co (NYSE:LLY)


Eli Lilly & Co (NYSE:LLY) is the second best general drug manufacturer stock with a Due Diligence Score of 59, which is 19 points higher than the general drug manufacturer industry average of 40. It passed 24 out of 38 due diligence checks and has strong fundamentals. Eli Lilly & Co has seen its stock return 17.35% over the past year, overperforming other general drug manufacturer stocks by 13 percentage points.

Eli Lilly & Co has an average 1 year price target of $1,035.08, an upside of 18.72% from Eli Lilly & Co's current stock price of $871.86.

Eli Lilly & Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Eli Lilly & Co, 92.31% have issued a Strong Buy rating, 7.69% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Astrazeneca (NASDAQ:AZN)


Astrazeneca (NASDAQ:AZN) is the third best general drug manufacturer stock with a Due Diligence Score of 57, which is 17 points higher than the general drug manufacturer industry average of 40. It passed 22 out of 38 due diligence checks and has strong fundamentals. Astrazeneca has seen its stock return 21.99% over the past year, overperforming other general drug manufacturer stocks by 18 percentage points.

What are the general drug manufacturer stocks with highest dividends?

Out of 13 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Pfizer (NYSE:PFE)


Pfizer (NYSE:PFE) has an annual dividend yield of 4.91%, which is 2 percentage points higher than the general drug manufacturer industry average of 3%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 219.7% indicates that its high dividend yield might not be sustainable for the long-term.

2. Gsk (NYSE:GSK)


Gsk (NYSE:GSK) has an annual dividend yield of 4.26%, which is 1 percentage points higher than the general drug manufacturer industry average of 3%. Gsk's dividend payout is not stable, having dropped more than 10% ten times in the last 10 years. Gsk's dividend has not shown consistent growth over the last 10 years.

Gsk's dividend payout ratio of 98.5% indicates that its high dividend yield might not be sustainable for the long-term.

3. Sanofi (NASDAQ:SNY)


Sanofi (NASDAQ:SNY) has an annual dividend yield of 3.77%, which is 1 percentage points higher than the general drug manufacturer industry average of 3%. Sanofi's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 88.1% indicates that its dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks up?

General drug manufacturer stocks were up 0.56% in the last day, and up 0.44% over the last week. Organon & Co was the among the top gainers in the drug manufacturers - general industry, gaining 11.02% yesterday.

Organon shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results.

What are the most undervalued general drug manufacturer stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued general drug manufacturer stocks right now are:

1. Astrazeneca (NASDAQ:AZN)


Astrazeneca (NASDAQ:AZN) is the most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Astrazeneca has a valuation score of 86, which is 47 points higher than the general drug manufacturer industry average of 39. It passed 6 out of 7 valuation due diligence checks.

Astrazeneca's stock has gained 21.99% in the past year. It has overperformed other stocks in the general drug manufacturer industry by 18 percentage points.

2. Biogen (NASDAQ:BIIB)


Biogen (NASDAQ:BIIB) is the second most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Biogen has a valuation score of 86, which is 47 points higher than the general drug manufacturer industry average of 39. It passed 6 out of 7 valuation due diligence checks.

Biogen's stock has dropped -38.91% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -43 percentage points.

3. Grifols Sa (NASDAQ:GRFS)


Grifols Sa (NASDAQ:GRFS) is the third most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Grifols Sa has a valuation score of 57, which is 18 points higher than the general drug manufacturer industry average of 39. It passed 4 out of 7 valuation due diligence checks.

Grifols Sa's stock has dropped -10.97% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -15 percentage points.

Are general drug manufacturer stocks a good buy now?

38.46% of general drug manufacturer stocks rated by analysts are a strong buy right now. On average, analysts expect general drug manufacturer stocks to rise by 18.66% over the next year.

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 93.77x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.